CN113801650B - 一种巯基β-环糊精-金纳米簇及其制备方法和应用 - Google Patents
一种巯基β-环糊精-金纳米簇及其制备方法和应用 Download PDFInfo
- Publication number
- CN113801650B CN113801650B CN202110988479.4A CN202110988479A CN113801650B CN 113801650 B CN113801650 B CN 113801650B CN 202110988479 A CN202110988479 A CN 202110988479A CN 113801650 B CN113801650 B CN 113801650B
- Authority
- CN
- China
- Prior art keywords
- cyclodextrin
- beta
- cholesterol
- auncs
- fluorescence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000010931 gold Substances 0.000 title claims abstract description 80
- 229910052737 gold Inorganic materials 0.000 title claims abstract description 71
- 125000003396 thiol group Chemical group [H]S* 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 268
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 132
- 239000000243 solution Substances 0.000 claims abstract description 62
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 29
- 239000002253 acid Substances 0.000 claims abstract description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims abstract description 21
- 239000001116 FEMA 4028 Substances 0.000 claims abstract description 14
- 229960004853 betadex Drugs 0.000 claims abstract description 14
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims abstract description 13
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims abstract description 13
- 238000001514 detection method Methods 0.000 claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000007864 aqueous solution Substances 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 238000010438 heat treatment Methods 0.000 claims abstract description 4
- 230000035484 reaction time Effects 0.000 claims description 22
- 238000006243 chemical reaction Methods 0.000 claims description 20
- 239000002245 particle Substances 0.000 claims description 10
- 238000000746 purification Methods 0.000 claims description 3
- 239000012798 spherical particle Substances 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 abstract description 12
- 238000002474 experimental method Methods 0.000 abstract description 7
- 230000035945 sensitivity Effects 0.000 abstract description 4
- 230000000694 effects Effects 0.000 description 45
- 230000004044 response Effects 0.000 description 30
- 230000015572 biosynthetic process Effects 0.000 description 28
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 25
- 238000003786 synthesis reaction Methods 0.000 description 23
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 15
- 239000002105 nanoparticle Substances 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- 238000002189 fluorescence spectrum Methods 0.000 description 10
- 238000010790 dilution Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- 230000007423 decrease Effects 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- VYXSBFYARXAAKO-WTKGSRSZSA-N chembl402140 Chemical compound Cl.C1=2C=C(C)C(NCC)=CC=2OC2=C\C(=N/CC)C(C)=CC2=C1C1=CC=CC=C1C(=O)OCC VYXSBFYARXAAKO-WTKGSRSZSA-N 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000011067 equilibration Methods 0.000 description 5
- 230000005284 excitation Effects 0.000 description 5
- 238000002795 fluorescence method Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000000862 absorption spectrum Methods 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- 239000000956 alloy Substances 0.000 description 4
- 229910045601 alloy Inorganic materials 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- -1 beta-cyclodextrin modified gold Chemical class 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000002329 infrared spectrum Methods 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 150000002343 gold Chemical class 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000001022 rhodamine dye Substances 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XYYVDQWGDNRQDA-UHFFFAOYSA-K trichlorogold;trihydrate;hydrochloride Chemical compound O.O.O.Cl.Cl[Au](Cl)Cl XYYVDQWGDNRQDA-UHFFFAOYSA-K 0.000 description 2
- HBOMLICNUCNMMY-KJFJCRTCSA-N 1-[(4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-KJFJCRTCSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- HYTUQENVFPSZBW-UHFFFAOYSA-N O.O.O.O=C1N[ClH](=O)NC2=C1NC(=O)N2 Chemical compound O.O.O.O=C1N[ClH](=O)NC2=C1NC(=O)N2 HYTUQENVFPSZBW-UHFFFAOYSA-N 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 238000000026 X-ray photoelectron spectrum Methods 0.000 description 1
- DEXQPYRMGAFOIW-UHFFFAOYSA-N [N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[K+].[K+].[K+].[K+] Chemical compound [N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[K+].[K+].[K+].[K+] DEXQPYRMGAFOIW-UHFFFAOYSA-N 0.000 description 1
- IHDHSOMDVDGJAD-UHFFFAOYSA-N [N+](=O)([O-])[O-].[Na+].[Na+].[Na+].[Na+].[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[N+](=O)([O-])[O-] Chemical compound [N+](=O)([O-])[O-].[Na+].[Na+].[Na+].[Na+].[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[N+](=O)([O-])[O-] IHDHSOMDVDGJAD-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- QZPSXPBJTPJTSZ-UHFFFAOYSA-N aqua regia Chemical compound Cl.O[N+]([O-])=O QZPSXPBJTPJTSZ-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 101150113720 aunc gene Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000001278 effect on cholesterol Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000024 high-resolution transmission electron micrograph Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 231100000405 induce cancer Toxicity 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000006862 quantum yield reaction Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229940043267 rhodamine b Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000002277 temperature effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000005641 tunneling Effects 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/02—Use of particular materials as binders, particle coatings or suspension media therefor
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y20/00—Nanooptics, e.g. quantum optics or photonic crystals
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/08—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials
- C09K11/58—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials containing copper, silver or gold
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Materials Engineering (AREA)
- Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Optics & Photonics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Inorganic Chemistry (AREA)
- Manufacturing & Machinery (AREA)
- Composite Materials (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110988479.4A CN113801650B (zh) | 2021-08-26 | 2021-08-26 | 一种巯基β-环糊精-金纳米簇及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110988479.4A CN113801650B (zh) | 2021-08-26 | 2021-08-26 | 一种巯基β-环糊精-金纳米簇及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113801650A CN113801650A (zh) | 2021-12-17 |
CN113801650B true CN113801650B (zh) | 2023-07-14 |
Family
ID=78941997
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110988479.4A Active CN113801650B (zh) | 2021-08-26 | 2021-08-26 | 一种巯基β-环糊精-金纳米簇及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113801650B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114769609B (zh) * | 2022-03-29 | 2024-04-09 | 华南理工大学 | 主客体化学介导尺寸可控发光金纳米粒子组装体及其制备方法与应用 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104198740A (zh) * | 2014-07-29 | 2014-12-10 | 中山大学 | 一种对葡萄糖和胆固醇同步检测的纳米生物传感器 |
CN105417492A (zh) * | 2015-11-04 | 2016-03-23 | 安徽师范大学 | β-环糊精-金纳米粒子的制备方法以及胆固醇的检测方法 |
CN107556999A (zh) * | 2017-07-28 | 2018-01-09 | 安徽师范大学 | 金纳米团簇及其制备方法和应用 |
CN108949145A (zh) * | 2018-09-12 | 2018-12-07 | 福建医科大学 | 脲酶-金纳米团簇荧光材料及其制备方法 |
CN109181678A (zh) * | 2018-11-09 | 2019-01-11 | 云南大学 | 一种合成巯基-β-环糊精稳定的绿色荧光金纳米簇的方法及其应用 |
CN109520979A (zh) * | 2018-11-02 | 2019-03-26 | 闽南师范大学 | 一种血清中胆固醇的检测方法 |
CN110016043A (zh) * | 2019-05-10 | 2019-07-16 | 西北工业大学 | 一种具有发射白光性质的金纳米团簇及其制备方法 |
CN110079297A (zh) * | 2019-04-25 | 2019-08-02 | 云南大学 | 一种利用6-巯基-β环糊精合成蓝色荧光铜纳米簇的方法 |
CN110144207A (zh) * | 2019-04-25 | 2019-08-20 | 云南大学 | 一种光诱导合成红色荧光金纳米簇的方法及应用 |
CN111253930A (zh) * | 2020-02-08 | 2020-06-09 | 安徽师范大学 | 一种荧光金纳米簇及其制备方法和应用 |
-
2021
- 2021-08-26 CN CN202110988479.4A patent/CN113801650B/zh active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104198740A (zh) * | 2014-07-29 | 2014-12-10 | 中山大学 | 一种对葡萄糖和胆固醇同步检测的纳米生物传感器 |
CN105417492A (zh) * | 2015-11-04 | 2016-03-23 | 安徽师范大学 | β-环糊精-金纳米粒子的制备方法以及胆固醇的检测方法 |
CN107556999A (zh) * | 2017-07-28 | 2018-01-09 | 安徽师范大学 | 金纳米团簇及其制备方法和应用 |
CN108949145A (zh) * | 2018-09-12 | 2018-12-07 | 福建医科大学 | 脲酶-金纳米团簇荧光材料及其制备方法 |
CN109520979A (zh) * | 2018-11-02 | 2019-03-26 | 闽南师范大学 | 一种血清中胆固醇的检测方法 |
CN109181678A (zh) * | 2018-11-09 | 2019-01-11 | 云南大学 | 一种合成巯基-β-环糊精稳定的绿色荧光金纳米簇的方法及其应用 |
CN110079297A (zh) * | 2019-04-25 | 2019-08-02 | 云南大学 | 一种利用6-巯基-β环糊精合成蓝色荧光铜纳米簇的方法 |
CN110144207A (zh) * | 2019-04-25 | 2019-08-20 | 云南大学 | 一种光诱导合成红色荧光金纳米簇的方法及应用 |
CN110016043A (zh) * | 2019-05-10 | 2019-07-16 | 西北工业大学 | 一种具有发射白光性质的金纳米团簇及其制备方法 |
CN111253930A (zh) * | 2020-02-08 | 2020-06-09 | 安徽师范大学 | 一种荧光金纳米簇及其制备方法和应用 |
Non-Patent Citations (1)
Title |
---|
One-pot green synthesis of supramolecular B-cyclodextrin functionalized gold nanoclusters and their application for highly selective and sensitive fluorescent detection of dopamine;Mohamed Ibrahim Halawa et al.;《Sensors and Actuators, B: Chemical》;第254卷;第1017-1024页 * |
Also Published As
Publication number | Publication date |
---|---|
CN113801650A (zh) | 2021-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Das et al. | Biocompatible carbon dots derived from κ-carrageenan and phenyl boronic acid for dual modality sensing platform of sugar and its anti-diabetic drug release behavior | |
Halawa et al. | One-pot green synthesis of supramolecular β-cyclodextrin functionalized gold nanoclusters and their application for highly selective and sensitive fluorescent detection of dopamine | |
Tian et al. | SERS-based immunoassay and degradation of CA19-9 mediated by gold nanowires anchored magnetic–semiconductor nanocomposites | |
Liu et al. | Carbon dots based dual-emission silica nanoparticles as a ratiometric nanosensor for Cu2+ | |
Huang et al. | Carbon quantum dots: synthesis, properties, and sensing applications as a potential clinical analytical method | |
Hassanzadeh et al. | Specific fluorometric assay for direct determination of amikacin by molecularly imprinting polymer on high fluorescent g-C3N4 quantum dots | |
Ameen et al. | Visual monitoring of silver ions and cysteine using bi-ligand Eu-based metal organic framework as a reference signal: Color tonality | |
Zhao et al. | Hydrothermal synthesis of nitrogen-doped carbon quantum dots as fluorescent probes for the detection of dopamine | |
Li et al. | Group IV nanodots: Newly emerging properties and application in biomarkers sensing | |
Aswathy et al. | Cu2+ modulated BSA–Au nanoclusters: A versatile fluorescence turn-on sensor for dopamine | |
Liu et al. | Photonic crystal enhanced gold-silver nanoclusters fluorescent sensor for Hg2+ ion | |
Cao et al. | Sensitive monitoring and bioimaging intracellular highly reactive oxygen species based on gold nanoclusters@ nanoscale metal-organic frameworks | |
WO2013022152A1 (ko) | 사이클로덱스트린을 이용하여 표면증강라만산란 활성을 갖는 금속 나노입자의 제조방법 및 이에 따라 제조된 금속나노입자를 포함하는 바이오센서 | |
CN107782704B (zh) | 基于近红外荧光探针铜纳米簇的叶酸检测方法 | |
Cao et al. | A novel nitrogen and sulfur co-doped carbon dots-H2O2 chemiluminescence system for carcinoembryonic antigen detection using functional HRP-Au@ Ag for signal amplification | |
Hou et al. | Etching and anti-etching strategy for sensitive colorimetric sensing of H2O2 and biothiols based on silver/carbon nanomaterial | |
CN108504347B (zh) | 增强型双发射荧光复合材料及其制备方法和应用 | |
CN111590087B (zh) | 荧光金纳米簇的制备方法、制得的荧光金纳米簇及其应用 | |
Xue et al. | Application of Au or Ag nanomaterials for colorimetric detection of glucose | |
CN113801650B (zh) | 一种巯基β-环糊精-金纳米簇及其制备方法和应用 | |
Moaddab et al. | Green synthesis of silver/carbon dot nanoparticles from Malva Sylvestris for fluorescence determination of tetracycline | |
Karimzadeh et al. | A sensitive determination of morphine in plasma using AuNPs@ UiO-66/PVA hydrogel as an advanced optical scaffold | |
Yan et al. | Facile preparation of sulfur quantum dots involving β-cyclodextrin for ratiometric fluorescence/scattered light detection of acridine orange | |
Wang et al. | A highly selective fluorescent sensor for chlortetracycline based on histidine-templated copper nanoclusters | |
CN109781704B (zh) | 一种磁性表面增强拉曼光谱活性基底及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20211217 Assignee: Guilin Xianjingkuangbao Technology Development Co.,Ltd. Assignor: GUILIN University OF ELECTRONIC TECHNOLOGY Contract record no.: X2023980046674 Denomination of invention: A thiol group b- Cyclodextrin gold nanoclusters and their preparation methods and applications Granted publication date: 20230714 License type: Common License Record date: 20231109 Application publication date: 20211217 Assignee: Guilin Sensing Material Technology Co.,Ltd. Assignor: GUILIN University OF ELECTRONIC TECHNOLOGY Contract record no.: X2023980046110 Denomination of invention: A thiol group b- Cyclodextrin gold nanoclusters and their preparation methods and applications Granted publication date: 20230714 License type: Common License Record date: 20231107 Application publication date: 20211217 Assignee: Guilin Xingyuan Technology Co.,Ltd. Assignor: GUILIN University OF ELECTRONIC TECHNOLOGY Contract record no.: X2023980045835 Denomination of invention: A thiol group b- Cyclodextrin gold nanoclusters and their preparation methods and applications Granted publication date: 20230714 License type: Common License Record date: 20231107 |